AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMURON LTD

0.034

-0.001-2.86%

Volume:8K

Turnover:282

Market Cap:10.98M

PE:-1.86

High:0.034

Open:0.034

Low:0.034

Close:0.035

52wk High:0.098

52wk Low:0.026

Shares:322.85M

Float Shares:265.37M

Volume Ratio:3.46

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.023

ROE:-39.68%

ROA:-21.93%

PB:0.84

PE(LYR):-1.51

Loading ...

Overview Company News Filings

Immuron CEO Lydeamore Presents at Emerging Growth Conference

Immuron Posts CEO Presentation for TechKnow Invest Roadshow

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

THOMSON REUTERS

Immuron Logs FY Global Sales A$7.7 Million

Immuron - FY26 Global Sales A$7.7 Mln, up 6% on Prior Comparative Period

THOMSON REUTERS

Australia's Immuron Rises as Company Seeks Partnership for New Drug

Immuron - Seeks Partners to Advance Clinical Development of Imm-529

THOMSON REUTERS

Immuron says unaware of undisclosed information behind recent trading move after ASX query

Immuron files Form 3 for Chief Commercial Officer Flavio Palumbo

Immuron files Form 3 as director Daniel Jude Pollock reports beneficial ownership

Immuron files Form 3 for Chairman Paul Gerard Brennan initial beneficial ownership statement

Immuron files Form 3 for Chief Scientific Officer Jerry Kanellos

Immuron files initial beneficial ownership statement for director Jeannette Anne Joughin

Immuron CEO Steven Lydeamore files initial beneficial ownership statement

Immuron files Form 3 as director Ravi Savarirayan reports beneficial ownership

Emerging Growth Research raises Immuron price target to $4, keeps Buy-Extended rating

Immuron Q3 sales rise 16% to AUD 1.5 million

Immuron Double Digit 3Q Sales Growth

THOMSON REUTERS

BUZZ-Australia's Immuron jumps on upbeat quarterly sales growth

BRIEF-Immuron Global Q3 Sales AUD$1.5 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IMC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.034,"timestamp":1787292720000,"preClose":0.035,"halted":0,"volume":8300,"delay":0,"changeRate":-0.028571428571428595,"nameEN":"IMMURON LTD","floatShares":265374293,"shares":322848081,"eps":-0.018314,"marketStatus":"Market Closed","change":-0.001,"latestTime":"08-21 16:12:00 AEST","open":0.034,"high":0.034,"low":0.034,"amount":282,"amplitude":0,"askPrice":0.037,"askSize":56317,"bidPrice":0.034,"bidSize":271700,"shortable":3,"etf":0,"ttmEps":-0.018314,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.035,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":3.46323970502344,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMC.AU","preClose":0.039,"auctionPrice":0.037,"auctionVolume":483,"auction":3,"marketStatus":"盘后竞价","timestamp":1787119743858}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":265374293,"roa":"-21.93%","roe":"-39.68%","lyrEps":-0.022586,"volumeRatio":3.46323970502344,"shares":322848081,"dividePrice":0,"high":0.034,"amplitude":0,"preClose":0.035,"low":0.034,"week52Low":0.026,"pbRate":"0.84","psRate":"1.47","week52High":0.098,"institutionHeld":0,"latestPrice":0.034,"committee":0.656621,"eps":-0.018314,"divideRate":0,"volume":8300,"delay":0,"ttmEps":-0.018314,"open":0.034,"prevYearClose":0.036,"prevWeekClose":0.039,"prevMonthClose":0.036,"prevQuarterClose":0.033,"fiveDayClose":0.039,"twentyDayClose":0.038,"sixtyDayClose":0.044},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659538801","title":"Immuron CEO Lydeamore Presents at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2659538801","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659538801?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:06","pubTimestamp":1786615589,"startTime":"0","endTime":"0","summary":"Immuron CEO Lydeamore presents at Emerging Growth ConferenceImmuron CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on Aug. 19, 2026.Slot scheduled for 4:25 p.m. to 4:35 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1G4s0n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017922","title":"Immuron Posts CEO Presentation for TechKnow Invest Roadshow","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017922?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:04","pubTimestamp":1785153842,"startTime":"0","endTime":"0","summary":"Immuron posts CEO presentation for TechKnow Invest RoadshowImmuron published a CEO presentation for the TechKnow Invest Roadshow held today at Sofitel Melbourne on Collins.Presentation highlights Trav","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8qcsxf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651344388","title":"Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2651344388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651344388?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:00","pubTimestamp":1784196001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUA1KDQZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651492718","title":"Immuron Logs FY Global Sales A$7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2651492718","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651492718?lang=en_us&edition=fundamental","pubTime":"2026-07-16 09:26","pubTimestamp":1784165163,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Logs FY Global Sales A$7.7 MillionJuly 16 (Reuters)-Immuron LtdIMC.AX:FY26 GLOBAL SALES A$7.7 MILLION, UP 6% ON PRIOR COMPARATIVE PERIODFurther company coverage:IMC.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43H1K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651494298","title":"Immuron - FY26 Global Sales A$7.7 Mln, up 6% on Prior Comparative Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2651494298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651494298?lang=en_us&edition=fundamental","pubTime":"2026-07-16 08:22","pubTimestamp":1784161372,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43H1K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649610841","title":"Australia's Immuron Rises as Company Seeks Partnership for New Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2649610841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649610841?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:45","pubTimestamp":1783305926,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron rises as company seeks partnership for new drug** Shares of Australia's ImmuronIMC.AXrise 11.1% to A$0.040, hitting their highest level since June 4** Stock marks its biggest intraday pct gain since June 1** The biopharmaceutical company says it is employing an advisory firm to help seek a partner to support clinical and commercial development of IMM-529** The IMM-529 is a product that can treat/prevent Clostridioides difficile infection, a contagious bacterial infection of the large intestine** Immuron stock up 11.1%, YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4N438046:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649661126","title":"Immuron - Seeks Partners to Advance Clinical Development of Imm-529","url":"https://stock-news.laohu8.com/highlight/detail?id=2649661126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649661126?lang=en_us&edition=fundamental","pubTime":"2026-07-06 07:19","pubTimestamp":1783293564,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nFWN4350F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638269897","title":"Immuron says unaware of undisclosed information behind recent trading move after ASX query","url":"https://stock-news.laohu8.com/highlight/detail?id=2638269897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638269897?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:02","pubTimestamp":1779969769,"startTime":"0","endTime":"0","summary":"Immuron told ASX it was not aware of any unannounced information that could explain recent trading in its securities.Pointed to a previously disclosed CEO presentation at the Emerging Growth Conference in the U.S. on May 8, 2026.Confirmed compliance with ASX Listing Rules, including Listing Rule 3.1 on continuous disclosure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7lhMB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635728717","title":"Immuron files Form 3 for Chief Commercial Officer Flavio Palumbo","url":"https://stock-news.laohu8.com/highlight/detail?id=2635728717","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635728717?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:02","pubTimestamp":1778788976,"startTime":"0","endTime":"0","summary":"Immuron Form 3 showed Chief Commercial Officer Flavio Palumbo held 1,142,909 ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL2vQ5Kc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635972871","title":"Immuron files Form 3 as director Daniel Jude Pollock reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2635972871","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635972871?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:02","pubTimestamp":1778788925,"startTime":"0","endTime":"0","summary":"Immuron director Daniel Jude Pollock reported ownership of 743,230 ordinary shares as of March 18, 2026.Filing also showed options on 1.33 million ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1NzrX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633962617","title":"Immuron files Form 3 for Chairman Paul Gerard Brennan initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633962617","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633962617?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:45","pubTimestamp":1777934756,"startTime":"0","endTime":"0","summary":"Immuron Form 3 filing shows chairman Paul Gerard Brennan holds stock options for 1.67 million ordinary shares, exercisable at USD 0.18 and USD 0.08.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL1T30Jg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631523085","title":"Immuron files Form 3 for Chief Scientific Officer Jerry Kanellos","url":"https://stock-news.laohu8.com/highlight/detail?id=2631523085","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631523085?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:03","pubTimestamp":1777493024,"startTime":"0","endTime":"0","summary":"Immuron Form 3 showed Chief Scientific Officer Jerry Kanellos held 333,000 ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLCZk9J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631952344","title":"Immuron files initial beneficial ownership statement for director Jeannette Anne Joughin","url":"https://stock-news.laohu8.com/highlight/detail?id=2631952344","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631952344?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:01","pubTimestamp":1777492901,"startTime":"0","endTime":"0","summary":"Immuron director Jeannette Anne Joughin filed an initial SEC Form 3 disclosing direct options for 1.33 million ordinary shares at exercise prices of USD 0.09 and USD 0.08.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL7FJp2c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631440523","title":"Immuron CEO Steven Lydeamore files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631440523","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631440523?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:01","pubTimestamp":1777492886,"startTime":"0","endTime":"0","summary":"Immuron CEO Steven George Lydeamore filed an initial SEC Form 3 reporting direct ownership of 3.16 million ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4Sq0P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631523159","title":"Immuron files Form 3 as director Ravi Savarirayan reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2631523159","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631523159?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:00","pubTimestamp":1777492859,"startTime":"0","endTime":"0","summary":"Immuron disclosed director Ravi Savarirayan held 877,840 ordinary shares as of March 18, 2026.Filing also reported Savarirayan held options covering 1.33 million ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLQHc3k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629445600","title":"Emerging Growth Research raises Immuron price target to $4, keeps Buy-Extended rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2629445600","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629445600?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:12","pubTimestamp":1776863539,"startTime":"0","endTime":"0","summary":"Emerging Growth Research raised its 12-month price target on Immuron to $4 from $3.9, maintaining a Buy-Extended rating.Report cited global product revenue of AUD 1.5 million in 3Q FY2026, up 16% year over year.Travelan sales drove growth in Australia, while U.S. revenue rose 1% in AUD terms due to foreign exchange effects.Analyst highlighted FDA clearance for Immuron to start Phase 2 trials of IMM-529 for C. difficile infections.Valuation case used a peer EV/revenue multiple of 6.22x, implying enterprise value near $33.3 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL2YM8s1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277871","title":"Immuron Q3 sales rise 16% to AUD 1.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277871","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628277871?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:01","pubTimestamp":1776420113,"startTime":"0","endTime":"0","summary":"Immuron posted unaudited global Travelan Q3 sales of AUD 1.5 million, up 16% year over year.Year-to-date sales to March 2026 reached AUD 5.7 million, up 7% from prior comparative period.Australia Q3 sales rose to AUD 0.9 million, up 15% year over year.U.S. Q3 sales were AUD 0.5 million, up 1% year over year.Canada Q3 sales were AUD 0.1 million, up more than 100% year over year; sales rose 82% from prior quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL1hqHXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IMC.AU","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","BK7508","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK7067","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628272735","title":"Immuron Double Digit 3Q Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2628272735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628272735?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:00","pubTimestamp":1776420000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nTUA7B0JLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628299962","title":"BUZZ-Australia's Immuron jumps on upbeat quarterly sales growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2628299962","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628299962?lang=en_us&edition=fundamental","pubTime":"2026-04-17 10:54","pubTimestamp":1776394474,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron jumps on upbeat quarterlysales growth** Shares of Immuron IMC.AX surge as much as 27.6% to A$0.037, their highest level since January 29, 2026** On track to log steepest intraday pct rise since July 17, 2025** Biopharmaceutical firm posts quarterly global sales of A$1.5 million  for its immune supplement Travelen, 16% higher than a year ago** About 2 million shares change hands, 8.7 times the 30-day avg  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N41006A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628696223","title":"BRIEF-Immuron Global Q3 Sales AUD$1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628696223","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628696223?lang=en_us&edition=fundamental","pubTime":"2026-04-17 09:06","pubTimestamp":1776388014,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Global Q3 Sales AUD$1.5 MillionApril 17 (Reuters) - Immuron Ltd IMC.AX:GLOBAL Q3 SALES AUD$1.5 MILLIONFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nFWN40Z19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}